RT Journal Article SR Electronic T1 Combination Therapy with VP16 and Ethinylestradiol for Hormone-Refractory Prostate Cancer: Good Response with Tolerability JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 3737 OP 3745 VO 30 IS 9 A1 HARUHITO AZUMA A1 TERUO INAMOTO A1 KIYOSHI TAKAHARA A1 NAOKAZU IBUKI A1 KOHEI KOYAMA A1 SYNYA UTIMOTO A1 YUTAKA FUJISUE A1 HIROHUMI UEHARA A1 KAZUMASA KOMURA A1 HAYAHITO NOMI A1 TAKANOBU UBAI A1 YOJI KATSUOKA YR 2010 UL http://ar.iiarjournals.org/content/30/9/3737.abstract AB Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.